Cabazitaxel for castration-resistant prostate cancer

The Lancet

Volumn 377, Issue 9760, 2011, Pages 121-

  Shigeta, Keisuke ^a   Miura, Yuji ^a   Naito, Yoichi ^a   Takano, Toshimi ^a  

^a TORANOMON HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CABAZITAXEL; DOCETAXEL; MITOXANTRONE; PREDNISONE;

CASTRATION; DIARRHEA; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; LETTER; MORTALITY; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSTATE CANCER;

EID: 79251531120     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(11)60012-3     Document Type: Letter

References (3)

1. JS de Bono, S Oudard, M Ozguroglu for the TROPIC Investigators Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial Lancet 376 2010 1147 1154
2. AC Mita, LJ Denis, EK Rowinsky Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors Clin Cancer Res 15 2009 723 730
3. X Pivot, P Koralewski, JL Hidalgo A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients Ann Oncol 19 2008 1547 1552